A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Thyroid Eye Disease

In brief

This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod PH20 SC in participants with active, moderate-to-severe TED, compared with placebo PH20 SC. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive efgartigimod PH20 SC or placebo PH20 SC, respectively during the double-blinded treatment period (DBTP). At the end of the DBTP, participants may enter a follow-up observational period while off study drug. Some participants may also enter the open-label treatment period with efgartigimod PH20 SC. The study duration varies from approximately 60 to 110 weeks. An alternative list of clinical sites open for recruitment could be found in the other UplighTED study record (https://www.clinicaltrials.gov/study/NCT06307626). This study was terminated early on 15 December 2025 as the pre-defined interim analysis concluded that continuing the trials is unlikely to demonstrate the intended efficacy. This decision is not related to safety concerns, and the safety profile of efgartigimod remains unchanged. End-of-study and Safety-Follow-Up visits are ongoing for the participants of this trial.

Key facts

Study ID

NCT06307613

Run by

argenx

People needed

102

Starts

2024-03-27

Expected to finish

2026-02-12

Last updated by the study team

2026-03-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The participant is at least 18 years of age
• The participant is capable of providing signed informed consent and following with protocol requirements
• The investigator determines active, moderate-to-severe thyroid eye disease (TED) associated with autoimmune thyroid conditions (Graves' disease or Hashimoto's thyroiditis) for the most severely affected eye
• The participant has first onset of active TED symptoms within 12 months before screening
• The participant must have normal thyroid function with the baseline disease under control or have mild hypo or hyperthyroidism at screening. Every effort should be made to correct the mild hypo or hyperthyroidism promptly and to maintain the normal thyroid function for the full duration of the study
• The participant agrees to use birth control consistent with local regulations and the people of child-bearing potential must have a negative blood pregnancy test at screening and a negative urine pregnancy test before receiving the study drug

You may not qualify if…

• Optic neuropathy (damage to optic nerve), defined as new visual field defect (blind spot), relative afferent pupillary defect (pupils respond differently to light), or color defect secondary to optic nerve involvement within the 6 months before screening
• Corneal decompensation (swelling of the cornea) unresponsive to medical management
• Previous orbital irradiation or surgery for TED
• Use of some medications before screening (more information is found in the protocol)
• Known autoimmune disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of TED or puts the participant at undue risk
• History of malignancy, cancer, unless considered cured by adequate treatment with no evidence of recurrence for ≥3 years. Adequately treated participants with the following cancers can be included at any time: Basal cell or squamous cell skin cancer, Carcinoma in situ of the cervix, Carcinoma in situ of the breast, Incidental histological findings of prostate cancer
• Clinically significant active infection that is not sufficiently resolved in the investigator's opinion or positive serum test at screening for active infection with any of the following: Hepatitis B virus (HBV), Hepatitis C virus (HCV), HIV
• Current participation in another interventional clinical study or previous participation in an efgartigimod clinical study and at least 1 dose of study drug received or has received at least 1 dose of commercially available efgartigimod
• Known hypersensitivity to study drug or one of its excipients (inactive ingredients)
• History of or current alcohol, drug, or medication abuse within 12 months before screening as assessed by the investigator
• Pregnant or lactating state or intention to become pregnant during the study
• Live or live-attenuated vaccine received <4 weeks before screening
• The complete list of exclusion criteria can be found in the protocol.

Where it is running

• UCI Health - Gavin Herbert Eye Institute — Irvine, California, United States
• University Of Southern California - Keck School Of Medicine — Los Angeles, California, United States
• Silkiss Eye Surgery — San Francisco, California, United States
• Advanced Research LLC — Coral Springs, Florida, United States
• Levenson Eye Associates — Jacksonville, Florida, United States
• Bascom Palmer Eye Institute — Miami, Florida, United States
• University of South Florida (USF) Health - Morsani Center for Advanced Healthcare — Tampa, Florida, United States
• University of Illinois Chicago — Chicago, Illinois, United States
• Wilmer Eye Institute — Baltimore, Maryland, United States
• University of Michigan — Ann Arbour, Michigan, United States
• Moyes Eye Center - Northland — Kansas City, Missouri, United States
• Quest Diagnostics - Mercy Smith Glynn Callaway — Springfield, Missouri, United States
• Duke University — Durham, North Carolina, United States
• Penn Medicine - Penn Presbyterian Medical Center - Scheie Eye Institute — Philadelphia, Pennsylvania, United States
• West Virginia University Eye Institute — Morgantown, West Virginia, United States
• Centre for Eye Research Australia — Melbourne, Australia
• The University of Western Australia - Lions Eye Institute (LEI) — Nedlands, Australia
• North Shore Private Hospital — St Leonards, Australia
• Sydney Eye Hospital — Sydney, Australia
• CHU UVC Brugmann - Site Victor Horta — Brussels, Belgium
• Oxycom Medical Centre — Burgas, Bulgaria
• UMHAT Aleksandrovska - Diagnostic Consultative Center (DCC) Aleksandrova — Sofia, Bulgaria
• Medical Center Vereya EOOD - Vereya Medical Center (former Military Hospital) — Stara Zagora, Bulgaria
• St. Petka Eye Hospital - Eye Clinic St. Petka Varna — Varna, Bulgaria
• Thrive Health - Beverly Hills — Beverly Hills, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.